Nihon Shinyaku launched the 0.8-mg high-dose tablet of selexipag for the treatment of pulmonary arterial hypertension. It is intended to be used with the existing 0.2-mg and 0.4-mg tablets to improve patient medication adherence.
On 20 May 2026, Nihon Shinyaku launched selexipag (Uptravi 0.8-mg tablets), a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in patients unsuitable for surgical treatment.
The product is an IP receptor agonist. It acts on IP receptors in vascular smooth muscle cells to increase cAMP production, lowering pulmonary arterial pressure through vasodilation and suppression of vascular smooth muscle proliferation. The 0.2-mg and 0.4-mg tablets had previously been available, and the high-dose formulation is being introduced on the premise of stepwise dose adjustment.
The official drug price is ¥6,272.20 per tablet. The launch date was 20 May 2026, the marketing approval date was 13 February 2026, and the date of listing in the National Health Insurance drug price standard was 20 May of the same year. For adults, oral administration starts at 0.2 mg twice daily after meals, with increases of 0.2 mg per dose up to a maximum of 1.6 mg per dose twice daily for maintenance. Tables specify starting, incremental and maximum doses by body weight, and starting doses are also specified for children aged 2 and older.
The source of this article is CareNet, and the report is based on the company's news as supporting material.